Exemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).
The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.
The What's Next for Cancer Immunotherapy module covers the future of cancer immunotherapy such as understanding important trends, new developments, potential approvals and disease states with promising data.
This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Assistant Professor, Medicine
University of Wisconsin Carbone Cancer Center
After completing this activity, the participant should be better able to:
Continuing Education Information
Approximate Time to Complete: 30 minutes
Credit Available: April 25, 2019 - April 25, 2020
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-19-734-H01-P)
Type of Activity: Knowledge
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours. Designated for 0.2 pharmacotherapy contact hours for Advanced Practice Registered Nurses.
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.
Accreditation Council for Pharmacy Education
American Nurses Credentialing Center's Commission on Accreditation
Contact Hour: 0.50
Accreditation Council for Continuing Medical Education (MD/DO)
AMA PRA Category 1 Credit(s)™: 0.50
Accreditation Council for Continuing Medical Education (non-MD/DO)
AMA PRA Category 1 Credit(s)™: 0.50
Certificate of Participation (No Credit)
Certificate of Participation: 0.00
2019 Video Series: What's Next for Cancer Immunotherapy (Advances in Cancer Immunotherapy)
This activity is presented free of charge.